To critically review studies of the impact of atypical antipsychotics on cognitive deficits in patients with schizophrenia.
Participants included in the review
The inclusion criterion was patients with schizophrenia. Studies investigating the effects of atypical antipsychotics on neurocognitive functioning in geriatric patients with schizophrenia were excluded from the analysis. The participants in the included studies were patients with schizophrenia, schizoaffective disorders, or an unspecified psychosis.
Outcomes assessed in the review
Neuropsychological and neurocognitive function were assessed. The actual outcomes included in the review were reported neurocognitive improvements, and neurocognitive improvements following correction for multiple comparisons in the following test measures: attention subprocesses, executive function, working memory, learning and memory, visuospatial analysis, verbal fluency, digit-symbol substitution and fine motor function.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the reviewers performed the selection.
Assessment of study quality
Methodological quality was assessed using standards for the assessment of cognitive change in schizophrenia. These included pharmacological status at baseline; multiple study arms with random assignment; double-blind conditions; adequate duration of trial; clinically appropriate dosing strategies; appropriate content, properties and number of neurocognitive measures; appropriate sample size; and discrimination between cognitive enhancement and generalised clinical change. The authors do not state how the papers were assessed for quality, or how many of the reviewers performed the quality assessment.
extraction. The data were extracted for the following categories: author, year, diagnosis of patients, baseline neurocognitive assessment (medication status), multiple study arms with random assignment, double-blind condition, adequate duration, appropriate dosing (daily dose), appropriate test batteries, adequate sample size, assessment of neurocognitive or clinical relationships, reported neurocognitive improvements, and neurocognitive improvements after correction for multiple comparisons.
Methods of synthesis
How were the studies combined? The probabilities (p values) from two or more independent studies were combined using Fisher's method (see Other Publications of Related Interest no.1). Two meta-analyses were conducted to address the question of whether atypical antipsychotics improved neurocognitive performance in general. The first analysis combined the results from the 3 double-blind studies, whilst the second combined the results of the 12 open-label studies.
The authors made some corrections for multiple comparisons in each arm using an experimental p value (p<0.05), but did not finish the procedure. When a given study included multiple test measures, the average p value for that study was used in the statistical procedure. If multiple test measures were included in a single domain of cognitive functioning, the average p value for that domain was used in the statistical procedure.
Meta-analyses were also conducted to examine the effect of novel antipsychotic medications on specific domains of cognitive function. These combined all the studies that reported data for each domain. Corrections for multiple comparisons were not made in these meta-analyses, since this would have required setting a p value for each domain.
How were differences between studies investigated?
Heterogeneity does not appear to have been investigated.
Results of the review
Fifteen studies were included: 3 randomised and double-blind studies and 12 open-label studies, one of which included multiple study arms with random allocation. There were 10 studies of clozapine, 4 of risperidone, 1 of zotepine, 1 of ziprasidone, and 1 of aripiprazole. The number of participants was unclear.
Methodological quality results: pharmacological status at baseline was determined in 14 of the 15 studies; 4 studies used multiple study arms with random assignment; 3 studies used double-blind conditions; 14 studies were of adequate trial duration; 12 studies used clinically appropriate dosing strategies; 7 studies included neurocognitive batteries that were appropriate, while 3 additional studies used measures that were acceptable, yet limited in scope; 5 studies used an appropriate sample size; and 9 studies showed discrimination between cognitive enhancement and generalised clinical change.
After correcting for multiple comparisons, 2 of the 3 randomised double-blind studies demonstrated significant neurocognitive improvement on at least one test measure, following treatment with atypical antipsychotic medication compared with conventional antipsychotics. Seven of the 12 open-label studies demonstrated improvement following treatment with atypical antipsychotics. Overall, 9 of the 15 studies demonstrated improvement.
The meta-analysis of the 3 double-blind studies indicated that atypical antipsychotics were significantly more effective
